drugset / Trial / NCT00732381

Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)

NCT00732381 ↗

Phase 3 Completed 351 enrolled Organon and Co
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.

Timeline

Start
2008-08
Primary completion
2008-11
Completion
2008-11

Outcome

Met primary endpoint

registry analysis (unspecified test); Mometasone Furoate Nasal Spray vs Placebo Nasal Spray; p = 0.006; ANCOVA NCT00732381 ↗

paper the primary end point, was significantly (p < 0.001) greater with MFNS than with placebo PMID 21439168 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Mometasone furoate Other / unclassified 200 ug Intranasal